*This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
Mirum Pharmaceuticals:
My team has been reviewing Mirum Pharmaceuticals for close to two months, and despite its poor performance in the past month it remains one of top picks for the month of June.
MIRM is to release data collected on maralixibat on 6/5/21.
Tomorrow morning we are averaging up on our positions at $17.00. Our original entry was at $16.30.
Short term take profit @$20.00 Long Term take profit $26.00
If you want to see more, please like and follow us @SimplyShowMeTheMoney
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
Mirum Pharmaceuticals:
My team has been reviewing Mirum Pharmaceuticals for close to two months, and despite its poor performance in the past month it remains one of top picks for the month of June.
MIRM is to release data collected on maralixibat on 6/5/21. Tomorrow morning we are averaging up on our positions at $17.00. Our original entry was at $16.30.
Short term take profit @$20.00 Long Term take profit $26.00
If you want to see more, please like and follow us @SimplyShowMeTheMoney
관련 발행물
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.